Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study

被引:9
作者
Michaud, Kaleb [1 ,2 ]
Pedro, Sofia [1 ]
Wipfler, Kristin [1 ]
Agarwal, Ekta [3 ]
Katz, Patricia [4 ]
机构
[1] Natl Databank Rheumat Dis, Wichita, KS USA
[2] Univ Nebraska Med Ctr, 986270 Nebraska Med Ctr, Omaha, NE 68198 USA
[3] Pfizer Inc, Peapack, NJ USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
D O I
10.1002/acr.24611
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To understand medication, lifestyle, and clinical care changes of persons with rheumatoid arthritis (RA) during the first months (March 2020 through May 2020) of the COVID-19 pandemic in the US. Methods Data were collected from adults with RA participating in FORWARD, The National Databank for Rheumatic Diseases observational registry, who answered COVID-19 web-based surveys in May 2020 and previously provided baseline characteristics and medication use prior to the US COVID-19 pandemic. We compared medication changes by disease-modifying antirheumatic drug (DMARD) exposure in logistic models that were adjusted for age, sex, comorbidities including pulmonary and cardiovascular diseases, education level, health insurance status, RA disease activity, fatigue, and polysymptomatic distress. Results Of 734 respondents, 221 (30%) reported medication changes. Among respondents who experienced a medication change, i.e., "medication changers/changers," glucocorticoids (GCs) were more commonly used compared to respondents who did not experience a medication change ("non-changers") (33% versus 18%). Non-hydroxychloroquine conventional DMARDs were less commonly used in changers compared to non-changers pre-COVID-19 (49% versus 62%), and changers reported more economic hardship during the COVID-19 pandemic compared to non-changers (23% versus 15%). While JAK inhibitor use was associated with the likelihood of a medication change, with an odds ratio (OR) of 1.9 (95% confidence interval [95% CI] 1.0, 3.4), only pre-COVID GC use remained a strong predictor for medication change in multivariable models (OR 3.0 [95% CI 1.9, 4.9]). Change in care was observed to have a significant association with pulmonary disease (OR 2.9 [95% CI 1.3, 6.5]), worse RA disease activity (OR 1.1 [95% CI 1.0, 1.1]), and GC use (OR 1.6 [95% CI 1.0, 2.5]). While the incidence of medication changes was the same before and after the American College of Rheumatology (ACR) guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic were first published in April 2020, self-imposed changes in medication were approximately twice as likely before publication of the guidelines, and physician-guided changes were more likely after publication. Conclusion Persons with RA in the US made substantial medication changes during the first three months of the COVID-19 pandemic, and changes among persons with RA after publication of the ACR guidance in April 2020 were made with increased physician guidance.
引用
收藏
页码:1322 / 1331
页数:10
相关论文
共 27 条
  • [1] Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic
    Ahmed, Sakir
    Gasparyan, Armen Yuri
    Zimba, Olena
    [J]. RHEUMATOLOGY INTERNATIONAL, 2021, 41 (02) : 243 - 256
  • [2] Andersen M., 2020, SSRN ELECT J, DOI 10.2139/ssrn.3569368
  • [3] Perspectives of Patients With Rheumatic Diseases in the Early Phase ofCOVID-19
    Antony, Anna
    Connelly, Kathryn
    De Silva, Thilinie
    Eades, Laura
    Tillett, William
    Ayoub, Sally
    Morand, Eric
    [J]. ARTHRITIS CARE & RESEARCH, 2020, 72 (09) : 1189 - 1195
  • [4] Infections in rheumatoid arthritis
    Atzeni, Fabiola
    Masala, Ignazio Francesco
    di Franco, Manuela
    Sarzi-Puttini, Piercarlo
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (04) : 323 - 330
  • [5] Caplan L, 2007, J RHEUMATOL, V34, P696
  • [6] Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
    Favalli, Ennio Giulio
    Monti, Sara
    Ingegnoli, Francesca
    Balduzzi, Silvia
    Caporali, Roberto
    Montecucco, Carlomaurizio
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72 (10) : 1600 - 1606
  • [7] Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Gyorfi et al
    Gianfrancesco, Milena
    Hyrich, Kimme L.
    Yazdany, Jinoos
    Machado, Pedro M.
    Robinson, Philip C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (06)
  • [8] Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]
  • [9] HSU CY, 2019, ARTHRITIS RES THER, V21
  • [10] Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
    Kalil, A. C.
    Patterson, T. F.
    Mehta, A. K.
    Tomashek, K. M.
    Wolfe, C. R.
    Ghazaryan, V.
    Marconi, V. C.
    Ruiz-Palacios, G. M.
    Hsieh, L.
    Kline, S.
    Tapson, V.
    Iovine, N. M.
    Jain, M. K.
    Sweeney, D. A.
    El Sahly, H. M.
    Branche, A. R.
    Pineda, J. Regalado
    Lye, D. C.
    Sandkovsky, U.
    Luetkemeyer, A. F.
    Cohen, S. H.
    Finberg, R. W.
    Jackson, P. E. H.
    Taiwo, B.
    Paules, C. I.
    Arguinchona, H.
    Erdmann, N.
    Ahuja, N.
    Frank, M.
    Oh, M.
    Kim, E. -S.
    Tan, S. Y.
    Mularski, R. A.
    Nielsen, H.
    Ponce, P. O.
    Taylor, B. S.
    Larson, L. A.
    Rouphael, N. G.
    Saklawi, Y.
    Cantos, V. D.
    Ko, E. R.
    Engemann, J. J.
    Amin, A. N.
    Watanabe, M.
    Billings, J.
    Elie, M. -C.
    Davey, R. T.
    Burgess, T. H.
    Ferreira, J.
    Green, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) : 795 - 807